Celebrating
20 years of nature-inspired solutions
in human health,
community safety
and global sustainability

biodesign.asu.edu
In 2004, the Biodesign Institute at Arizona State University opened as a place where scientists collaborate across disciplines using inspiration from nature’s ingenuity to pioneer cutting-edge solutions.

These innovations have a profound and positive impact on people’s lives, transform our understanding of the natural world and drive tangible improvements in society.

By leveraging our expertise in biomedicine, technology and engineering, the Biodesign Institute is ready for what comes next.

We scientists and researchers have a privileged position in society — the opportunity to stand at the edge of knowledge and look forward to the future. The greatest reward comes when we can use that knowledge to improve the state of humanity.”

— Joshua L. LaBaer, MD, PhD
Executive Director, Biodesign Institute
Naturally occurring microorganisms remove contaminants from water through an ASU developed membrane biofilm reactor. The system provides the microorganisms with hydrogen gas, which must be present for them to change the chemical composition of a contaminant and render it harmless.

Obesity and the microbiome
Gut microbes play a role in regulating weight, according to research from ASU and Mayo Clinic. Modifying these bacteria could one day be a treatment option for obesity.

West Nile therapeutic
Scientists demonstrate the first plant-derived treatment to successfully combat West Nile virus after exposure and infection. Plants offer an inexpensive and effective “laboratory” for creating new treatments.

Early detection of breast cancer
Researchers discover powerful biomarkers for the early detection of breast cancer. The findings represent the first demonstration of a custom protein-array technology used to find biomarkers in breast cancer patients before clinical diagnosis.
Mobile health
Breezing, a spinout company, launches the world's first portable metabolism tracker. The device provides users with personalized metabolic information to help them adjust their diet and exercise regimens for maintaining or reaching a healthy weight.

Synthetic biology
Scientists reveal alternatives to DNA and RNA that are capable of sharing genetic information. The findings offer clues to early life, contribute to the search for life elsewhere in the universe and point to possible applications in molecular medicine.

FDA approves autism treatment study
The FDA approves a pilot treatment study of 20 children with autism, ages 7–17, with moderate to severe gastrointestinal problems. Through a process known as “fecal microbiota transplants,” researchers see an 80% reduction in gastrointestinal distress and a significant improvement in behavior.

ASU and Ebola
Two U.S. aid workers infected with Ebola virus recover after receiving an experimental treatment made using modified tobacco plants. ASU researchers developed the treatment, ZMapp, in collaboration with Mapp Biopharmaceutical and Kentucky BioProcessing.

Colon cancer links
New research details how inflammation triggers colon cancer cells to spread to other organs. The findings will enable researchers to identify new drug targets for the prevention and treatment of colon cancer.

DNA reader
A prototype DNA reader, developed with scientists from IBM Thomas J. Watson Research Center, could make whole-genome profiling an everyday practice in medicine by significantly reducing the cost.
A new study describes compulsive evolution and dramatic genetic diversity in cells belonging to acute myeloid leukemia. The results significantly alter existing assumptions of cancer progression, indicating much greater genetic diversity in AML than previously assumed.

Dramatic research shows that during pregnancy, cells of the fetus often migrate through the placenta, taking up residence in many areas of the mother’s body, potentially benefiting or undermining maternal health.

The FDA announces a ban on the sale of personal care products containing the antimicrobials triclosan and triclocarban. The agency uses findings from an ASU scientist and other researchers showing that long-term exposure to antibacterial products could pose health risks, such as bacterial resistance or hormonal effects.

Researchers investigate the role of mitochondria — the energy centers of cells — in the progression of Alzheimer’s disease. The study builds on earlier work suggesting gene mutations affecting mitochondrial function may be critical in the development and progression of the disease.

Popular Science names a low-cost Zika virus test — developed by researchers from Harvard University and ASU — a 2016 Best of What’s New award winner in the health category. The test uses a small strip of paper imprinted with a testing array that holds potential for diagnosing a broad range of infectious diseases, including Zika.
Multiple lines of evidence suggest that certain species of herpes viruses contribute to the development of Alzheimer’s disease. The study, performed with colleagues at Mount Sinai, clarifies the mechanisms by which infectious agents may play important roles in the disease.

The five-story, 191,000-square-foot building gives scientists more space to realize discovery and innovation goals. Biodesign Building C is the third of four facilities planned to accommodate the institute’s research efforts.

Improved Zika vaccine
An ASU-led team develops the world’s first plant-based Zika vaccine, which could be more potent, safer and cheaper to produce than any other efforts to date. The successful proof-of-concept offers hope for a first-phase human clinical trial.

Test for pancreatic cancer
A new technique identifies pancreatic cancer early in its development. The method relies on the sensitive detection of extracellular vesicles — tiny bubbles of material emitted from most living cells.

Rittmann wins Stockholm Water Prize
Biodesign researcher Bruce Rittmann receives the 2018 Stockholm Water Prize for microbiology research and innovations that have revolutionized water and wastewater treatment. The award is sometimes referred to as “the Nobel Prize of water.”

Nanorobots seek and destroy tumors
Nanobots are programmed to successfully shrink tumors by cutting off their blood supply. The successful demonstration of the technology is the first study of its kind in mammals.

Alzheimer’s viral connection
Multiple lines of evidence suggest that certain species of herpes viruses contribute to the development of Alzheimer’s disease. The study, performed with colleagues at Mount Sinai, clarifies the mechanisms by which infectious agents may play important roles in the disease.

Biodesign Building C opens
The five-story, 191,000-square-foot building gives scientists more space to realize discovery and innovation goals. Biodesign Building C is the third of four facilities planned to accommodate the institute’s research efforts.

Rittmann wins Stockholm Water Prize

Rittmann wins Stockholm Water Prize

Alzheimer’s viral connection

Alzheimer’s viral connection

Biodesign Building C opens

Biodesign Building C opens
ASU researchers shed light on an affordable, plant-based vaccine that stimulates a protective immune response against the HPV virus.

**Canine cancer trials begin**
In the largest canine research trial in history, a Biodesign team begins testing an anticancer vaccine. If the vaccine works in dogs, the researchers plan to test the vaccine in people.

**Plant-based HPV vaccine**
ASU researchers develop an “immunosilencing” technique that can make CRISPR-Cas9 gene editing safer and more reliable.

**Safer snipping**
Biodesign researchers develop an anticancer vaccine. If the vaccine works in dogs, the researchers plan to test the vaccine in people.

**COVID-19 saliva test**
Biodesign scientists develop the state’s first saliva-based test, which is the first in the United States to be made widely available to the public. The new test makes COVID-19 diagnostic testing easier and more readily available to Arizonans.

**1 million COVID tests**
ASU invents and develops enough COVID-19 tests to administer one to 1 in 7 Arizonans statewide.

**Clean water for spaceflight**
A first-of-its-kind study characterizes different bacterial populations isolated over many years from potable (drinking) water from the International Space Station.

**Insights into heart disease**
An ASU team captures a high-resolution structure that offers novel insights on an important drug target for improved treatment of cardiac disease.

**Epigenetic insights into dementia**
The largest study of its kind unveils new insights into how genes are regulated in Alzheimer’s, including discovering 84 new genes linked to the disease. ASU researchers joined international colleagues on this meta analysis.
Viruses vs. cancer
A combination therapy of cancer-fighting viruses in tandem with immunotherapy shows promise in the fight against intractable cancers. The approach uses immune T cells equipped with the myxoma virus to target and kill cancer cells as well as stimulate the immune system to fight the disease.

Roots of neurodegenerative disease
Research unveils common and unique hallmarks of six neurodegenerative diseases: amyotrophic lateral sclerosis (Lou Gehrig’s disease), Alzheimer’s disease, Friedreich’s ataxia, frontotemporal dementia, Huntington’s disease and Parkinson’s disease — opening the door to new approaches for therapy.

X-ray boon
The National Science Foundation awards $90.8 million in funding to Arizona State University — the largest NSF research award in the university’s history — to bring about a new era in X-ray science. The funding supports the creation of a first-of-its-kind compact X-ray free electron laser to propel advances in new medicines, renewable energy, quantum technologies, and semiconductor research and manufacturing.

First light
Scientists generate the first X-rays in the compact X-ray light source — a major milestone for the first-of-its-kind instrument.

Choline for the brain
Choline shows promise in the fight against Alzheimer’s disease, according to a new Biodesign-led study. Deficiencies in the common nutrient are associated with cognitive and motor deficits.

20th anniversary
As the Biodesign Institute marks its two-decade milestone of groundbreaking research and discoveries, we stand ready to harness our profound expertise to shape a future of enduring impact on health care, sustainability and security.